Apr 13, 2023

FendX Technologies: Reducing The Spread Of Pathogens With Nanotechnology

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a member of the MedicalGold.ca community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

FendX Technologies (CSE: FNDX) is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. Their first product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners including McMaster University. The Company has an exclusive worldwide license to its technology, including an IP portfolio, from McMaster.

This is a paid promotion on behalf of FendX.

Investment overview

FendX is backed by Canaccord Capital Markets, one of Canada’s leading global investment banks with healthcare sector expertise. Strong financial backing helps to position FendX to continue to develop its nanotechnology platform (see anticipated catalysts section below). Like many of the companies that MedicalGold covers, FendX is an early-stage company with proof-of-concept technology that is preparing for imminent growth.

With yesterdy's news, FendX announced that it has signed a development stage agreement with Dunmore International Corp., a Steel Partners Holdings L.P. (NYSE:SPLP) operating company, to provide their engineering expertise to scale-up FendX’s REPELWRAP™ film to create intermediate-sized prototype films for testing.

Dr. Carolyn Myers, CEO says this is an important milestone as they have successfully completed testing of a lab prototype with McMaster University and are now ready to transfer the process of making REPELWRAP™ film to Dunmore to continue with their prototype development milestones as a first step to assessing and creating an automated manufacturing process.

“We have successfully completed testing a lab prototype with McMaster University and are now ready to transfer the process for making REPELWRAP™ film to Dunmore to continue with our prototype development milestones to create larger versions of REPELWRAP™ film. The engagement of Dunmore is an important milestone for us as this is the first step to assessing and creating an automated manufacturing process.  We look forward to continuing to execute on our scale-up and development milestones with highly experienced collaborators and are excited to work with an experienced manufacturer such as Dunmore. We are committed to the further development and testing of REPELWRAP™ film, with the intention of developing a commercial product. Leveraging our robust patent portfolio and nanotechnology, the Company also plans to research and develop a pipeline of other products to contribute to the global effort to reduce the spread of pathogens.”
~ Dr. Carolyn Myers, FendX CEO

Anticipated catalysts

  • Commence scale-up and testing of intermediate prototype of REPELWRAP™ film (repel version) with Dunmore (April 2023) with estimated completion in Q3 2023
  • Complete development of REPELWRAP™ repel and kill lab prototype and scalability assessment testing with McMaster (Q3 2023)
  • Initiate scale-up activities of REPELWRAP™ repel and kill intermediate prototype and testing with a manufacturer (Q3 2023) with an estimated completion by Q2 2024
  • Complete commercial scale-up for REPELWRAP™ film (repel version) (Q2 2024)
  • Launch REPELWRAP™ film (repel version) in Canada (H2 2024)
  • Complete development of a lab prototype of a catheter coated with FendX’s nanotechnology (Q24 2024)

FendX has a tight free trading float due to the fact that ~70% of the common shares are currently subject to escrow and voluntary pooling restrictions.

Stock information


FendX has assembled an all-star management team with deep industry expertise in developing life sciences businesses, raising capital in the public markets, and pharmaceutical marketing and sales. Their CEO is an accomplished geneticist from the University of British Columbia who developed her business savvy skillset from her broad commercial and business development  experience in the pharmaceutical industry and from attending the Rutgers Executive MBA program. She is supported by a COO with extensive sales knowledge in biotech, and a CFO who led Wolverton Securities’ corporate finance and syndication department for 19 years. Detailed biographies below.

Dr. Carolyn Myers, MBA, PhD

President, Chief Executive Officer and Director

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading healthcare businesses. Dr. Myers is currently CEO of FendX Technologies Inc. She is also a Principal of BioEnsemble LLC, where she works closely with numerous start-ups and small pharma companies to assist them in developing their business strategy and planning. Her previous executive positions include Vice President International Business Development and Alliance Management at Allergan PLC, President of Dey Laboratories and President of Mylan Technologies Inc. Prior to serving in these roles, Dr. Myers served in various management positions in sales and marketing at Pharmacia Corporation., now a part of Pfizer, Inc. Dr. Myers is also a director at Mayne Pharma Group Ltd. and Hyloris Pharmaceuticals SA, both publicly listed companies. She earned her PhD in genetics from the University of British Columbia and her MBA from Rutgers University.

Andrea Mulder, BPHE, MBA

Chief Operating Officer

Andrea Mulder is an accomplished senior commercial healthcare executive with extensive sales and marketing experience leading launch strategies at leading pharmaceutical and biotechnology corporations in Canada.  Andrea Mulder is COO of FendX Technologies Inc. She has significant therapeutic knowledge across multiple therapeutic areas including infectious disease, immunology, neurology, respiratory and oncology and has been an active member of Global and Canadian leadership/ commercial teams at:  Eisai Canada, Ipsen, GlaxoSmithKline, Roche, Johnson and Johnson and Pfizer.  Andrea Mulder earned her degree at the University of Toronto in Health Sciences-Kinesiology and her EMBA in Global Leadership at the University of Fredericton, Canada.

Rose Zanic, CPA, CA

Chief Financial Officer

Rose Zanic has over 25 years’ of capital markets and corporate finance expertise. She is a self-employed corporate finance professional with significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration. She previously spent 19 years with Wolverton Securities Ltd. where she was Senior Vice-President, Corporate Finance in charge of that firm’s corporate finance and syndication departments.

Ms. Zanic holds a CPA, CA designation and received a Bachelor of Commerce degree from the University of British Columbia. She currently is a director and/or officer of several Canadian publicly listed companies and is also a member of the TSX Venture Exchange BC Local Advisory Committee.


FendX Technologies Inc. is a sponsor of Medical Gold.ca. Sponsors of MedicalGold.ca pay for one year of coverage in order to increase awareness of a product, service, person, company or idea. Coverage of sponsor companies is for information; illustrative purposes only. MedicalGold.ca  strives to increase awareness of companies while remaining as objective as possible. Nothing contained in articles; written interviews on MedicalGold.ca is an offer/solicitation to Buy or Sell securities. Readers are strongly advised to consult with their own licensed or registered financial advisors before making investment decisions. Micro-cap companies are highly speculative, investors in its securities could experience up to 100% loss of invested funds.


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.sedarplus.ca for important risk disclosures. It’s your money and your responsibility.